Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKC-2001
- Development stage
- Preclinical
- Lead developer
- Akrocell Biosciences
- Modality
- Cell Therapies
01
Overview
AKC-2001 is a preclinical-stage cell therapy being developed by Akrocell Biosciences for the treatment of knee cartilage damage. The therapy is built upon the proprietary SlabON® platform, a tissue structure formation technology that integrates biocompatible materials with cellular components to engineer regenerative tissue. According to company pipeline documentation, AKC-2001 utilizes hepatocytes (liver cells) to promote the repair and regeneration of knee cartilage. The project was selected for the South Korean Tech Incubator Program for Startup (TIPS) in July 2022 and is currently undergoing preclinical evaluation.
Beyond the preview
Go deeper on AKC-2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKC-2001.